相似文献
1
[3 years' data of tenofovir. Confirmed as a valuable building block].
MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:30-1.
2
Elvucitabine data released at CROI.
AIDS Patient Care STDS. 2010 Mar;24(3):198.
3
New once-daily HIV combination better tolerated.
Expert Rev Anti Infect Ther. 2004 Dec;2(6):826.
4
5
Raltegravir as effective as efavirenz in 144-week data.
AIDS Patient Care STDS. 2009 Aug;23(8):679-80.
6
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Med Mal Infect. 2013 Mar;43(3):134-5. doi: 10.1016/j.medmal.2013.01.008. Epub 2013 Feb 20.
7
[Valuable combination partner. Great benefit for therapy naive patients].
MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:82-4.
8
Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
J Infect Dis. 2005 Dec 1;192(11):1867-8. doi: 10.1086/498070. Epub 2005 Oct 25.
9
[Conclusions. Tenofovir].
Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:62-4. doi: 10.1157/13126273.
10
[HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
Allerg Immunol (Paris). 1998 Apr;30(4):123-4.
Zotero 插件